OncoSec Touts Encouraging Early Data For Opdivo Combined Immunotherapy For Skin Cancer

  • OncoSec Medical Incorporated ONCS announced early clinical data from an investigator-sponsored trial of TAVO in combination with Bristol-Myers Squibb Co's BMY intravenous Opdivo (nivolumab). 
  • TAVO is OncoSec's proprietary interleukin 12 (IL-12) encoding plasmid delivered by intratumoral electroporation (TAVO-EP).
  • The trial enrolled patients with high-risk operable locoregional advanced stage IIIB-D or stage IVA melanoma. 
  • Related: OncoSec Cuts Workforce, Prioritizes Pipeline.
  • A preoperative overall response rate was observed in 7 of 10 patients (70%) consisting of 4 patients with complete response (CR) and three patients with partial response (PR). 
  • Two patients had stable disease, and one showed progressive disease. 
  • One patient with a PR declined surgery due to a significant response after neoadjuvant treatment. 
  • At the time of surgery, 8 of 9 (88.9%) evaluated patients had a major pathologic response, and 6 of 9 patients (66.7%) had a pathological CR. No disease recurrence has been observed at a median follow-up of 7 months from the surgery date.
  • Overall, the combination treatment was well tolerated, and no patient discontinued neoadjuvant treatment due to toxicity. Patients continue to enroll.
  • Price Action: ONCS shares are up 1.99% at $4.10 during after-hours trading on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!